Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma

Annals of Otology, Rhinology and Laryngology

Volumn 115, Issue 8, 2006, Pages 607-610

  Bhattacharyya, Neil ^a,c   Chien, Wade ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Division of Otolaryngology   (United States)

Author keywords

Differentiated thyroid carcinoma; Radioactive iodine; Second primary malignancy

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DATA BASE; FEMALE; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 33747388725     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940611500806     Document Type: Article

References (20)

1. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer incidence in five continents. Vol 6. Lyon, France: International Agency for Research on Cancer, 1992.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
3. [Erratum in Am J Med 1995; 98:215.]
4. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003;128:118-23.
5. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med 1984;25:755-8.
6. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35:1418-22.
7. Schlumberger MJ, Travagli JP. Radioiodine scanning, ablation, and treatment. In: Randolph G, ed. Surgery of the thyroid and parathyroid glands. Philadelphia, Pa: WB Saunders, 2005: 465-77.
8. Brincker H, Hansen HS, Andersen AP. Induction of leukemia by 131-I treatment of thyroid carcinoma. Br J Cancer 1973;28:232-7.
9. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986;59: 45-51.
10. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995;36:21-7.
11. Bhattacharyya N, Nayak VK. Survival outcomes for second primary head and neck cancer: a matched analysis. Otolaryngol Head Neck Surg 2005;132:63-8.
12. Bhattacharyya N, Fried MP. Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 2005;26:39-44.
13. Shapiro NL, Bhattacharyya N. Population-based outcomes for pediatric thyroid carcinoma. Laryngoscope 2005;115: 337-40.
14. Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991;64:159-63.
15. de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997;75:734-9.
16. Hall P, Holm LE, Lundell G. Second primary tumors following thyroid cancer. A Swedish record-linkage study. Acta Oncol 1990;29:869-73.
17. Akslen LA, Glattre E. Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. Eur J Cancer 1992;28:491-5.
18. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92:225-31.
19. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638-44.
20. Edhemovic I, Volk N, Auersperg M. Second primary cancers following thyroid cancer in Slovenia. A population-based cohort study. Eur J Cancer 1998;34:1813-4.